Australia markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
63.08+0.50 (+0.80%)
At close: 04:00PM EDT
63.00 -0.08 (-0.13%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close62.58
Bid62.71 x 40000
Ask63.23 x 1800
Day's range61.85 - 63.13
52-week range57.17 - 74.12
Avg. volume8,285,567
Market cap79.122B
Beta (5Y monthly)0.38
PE ratio (TTM)17.62
EPS (TTM)3.58
Earnings date27 July 2022 - 01 Aug 2022
Forward dividend & yield2.92 (4.63%)
Ex-dividend date14 June 2022
1y target est69.21
  • Motley Fool

    3 Top Dividend Stocks for Generating Passive Income

    One great way to make passive income is to invest in dividend stocks. Here's why they selected AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Merck (NYSE: MRK). Keith Speights (AbbVie): Only the most elite dividend stocks become Dividend Kings.

  • Zacks

    Gilead (GILD) Announces Positive Data on Hepcludex for HDV

    Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.

  • Business Wire

    Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

    FOSTER CITY, Calif., June 24, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.